EU grants orphan-drug status to Threshold's sarcoma drug

03/18/2012 | Reuters

A compound by Threshold Pharmaceuticals to treat soft-tissue sarcoma received orphan-drug designation in the EU. The drug, which could get 10 years of market exclusivity, is being tested with standard chemotherapy doxorubicin in a Phase III study.

View Full Article in:


Published in Brief: